RESUMEN
RT Cardiac Systems (RTCS, Raleigh, NC) is developing an intravascular percutaneous mechanical circulatory support (pMCS) device drive system for use during high-risk percutaneous coronary intervention and emergent cardiogenic shock. The proprietary pMCS device (US patent 10,780,206) consists of a miniaturized axial flow pump with an integrated motor connected via a short flexible drive system. This novel flexible drive system creates a flexible pump that is advantageous for percutaneous placement and conforming to anatomy. This design also has the benefit of not requiring a continuous external lubrication source. In this article, we present engineering development and feasibility testing of the prototype pMCS system. Computational fluid dynamics (CFD) modeling was performed to evaluate candidate blade set designs (impeller leading and trailing edges, diffuser) and predict hydrodynamic performance and hemolysis risk. Bench testing of candidate lip seal designs (radial interference, durometer, and seal angle) was evaluated for leak rate. Two 16Fr prototype devices were then fabricated and tested in a static mock flow loop. Experimental testing demonstrated 3 L/min flow against 110 mmHg and 4 L/min flow against 80 mmHg, which matched the CFD-predicted hydrodynamic performance. These results demonstrate feasibility of the engineering design and performance of the prototype devices.
Asunto(s)
Corazón Auxiliar , Intervención Coronaria Percutánea , Humanos , Estudios de Factibilidad , Corazón Auxiliar/efectos adversos , Hemólisis , Choque Cardiogénico/cirugía , Diseño de EquipoRESUMEN
Controller algorithms are an important feature for assessment of ventricular assist device performance. Flow estimation is one algorithm implemented in the HeartWare continuous-flow ventricular assist device pump system. This parameter estimates flow passing through the pump and is calculated using speed, current, and hematocrit. In vitro and in vivo studies were conducted to assess the algorithm accuracy. During in vitro testing, three pumps were tested in four water-glycerol solutions at 37°C with viscosities equivalent to hematocrits of 20, 30, 40, and 50%. By using a linear regression model, a correlation coefficient of >0.94 was observed between measured and estimated flow for all conditions. In vivo studies (n = 9) were conducted in an ovine model where a reference flow probe was placed on the outflow graft and speed was adjusted from 1,800 to 4,000 revolutions per minute. During in vivo experiments, estimated pump flow (mean, minimum, and maximum) was compared with measured pump flow. The best-fit linear regression equation for the data is y = 0.96x + 0.54, r = 0.92. In addition, waveform fidelity was high (r > 0.96) in normal (i.e., nonsuction) cases where flow pulsatility was >2 L/min. The flow estimation algorithm demonstrated strong agreement with measured flow, both when analyzing average waveform magnitude and fidelity.
Asunto(s)
Corazón Auxiliar/normas , Flujo Pulsátil , Algoritmos , Animales , Velocidad del Flujo Sanguíneo , Diseño de Equipo , Modelos Cardiovasculares , OvinosRESUMEN
OBJECTIVE: Ventricular assist device (VAD) miniaturization is one design trend that may result in less-invasive implantation techniques and more versatility with patient selection. The MVAD System is a miniature, continuous-flow device implanted in the ventricle. The pump is capable of delivering between 0 and 7 L/min of flow at a mean arterial pressure of 75 mm Hg. The impeller was optimized from its original design to improve hydraulic performance, minimize shear regions, and enhance the impeller's radial stiffness. These studies evaluated the MVAD System with modified impeller in the preclinical setting. METHODS: This modified pump design was tested through chronic studies (n = 6) in a healthy ovine model where 4 animals were implanted for a duration of 30 ± 5 days and 2 animals were implanted for a duration of 90 ± 5 days. The pump was placed in the left ventricular apex with the outflow graft anastomosed to the descending aorta. Postoperatively, no anticoagulant or antiplatelet therapies were administered throughout the study duration. RESULTS: All 6 animals reached their elective date of kill, demonstrating no evidence of organ compromise or device-related complications. Average pump parameters did not deviate significantly, and average rotational speed, pump flow, and power consumption were 14095 ± 139 RPM, 4.1 ± 0.4 L/min, and 4.3 ± 0.1 W, respectively. Examination of pump components postexplant demonstrated no mechanical wear or thrombus formation. CONCLUSIONS: Hemocompatibility and biocompatibility of the modified MVAD System were demonstrated through pump parameters, blood chemistry panels, and histopathology analysis.
Asunto(s)
Corazón Auxiliar , Miniaturización/instrumentación , Algoritmos , Animales , Modelos Animales de Enfermedad , Estudios de Factibilidad , Insuficiencia Cardíaca/terapia , Ventrículos Cardíacos , Hemoglobinometría , Humanos , Ensayo de Materiales/instrumentación , Diseño de Prótesis/instrumentación , Diseño de Prótesis/métodos , Ovinos , Trombosis/etiología , Trombosis/prevención & controlRESUMEN
As a result of stagnant heart transplantation rates, ventricular assist devices (VADs) have become a widely accepted therapy for the treatment of advanced-stage heart failure. Long-term reliability of VADs will become increasingly vital as the population of destination therapy patients expands. In this study, eight HVAD pumps (n = 8) completed a 6-year reliability test in the HeartWare Life Cycle Testing System, an in-vitro mock circulatory loop that simulated physiologic pressures and flows. Cumulative runtime for the pumps was 2,408 ± 60 days. During this time, no device failures of any type occurred. These results strongly support the durability of the pump design.
Asunto(s)
Corazón Auxiliar , Falla de Prótesis , Humanos , Técnicas In Vitro , Reproducibilidad de los ResultadosRESUMEN
Implantation of ventricular assist devices (VADs) for the treatment of end-stage heart failure (HF) falls decidedly short of clinical demand, which exceeds 100,000 HF patients per year. Ventricular assist device implantation often requires major surgical intervention with associated risk of adverse events and long recovery periods. To address these limitations, HeartWare, Inc. has developed a platform of miniature ventricular devices with progressively reduced surgical invasiveness and innovative patient peripherals. One surgical implant concept is a transapical version of the miniaturized left ventricular assist device (MVAD). The HeartWare MVAD Pump is a small, continuous-flow, full-support device that has a displacement volume of 22 ml. A new cannula configuration has been developed for transapical implantation, where the outflow cannula is positioned across the aortic valve. The two primary objectives for this feasibility study were to evaluate anatomic fit and surgical approach and efficacy of the transapical MVAD configuration. Anatomic fit and surgical approach were demonstrated using human cadavers (n = 4). Efficacy was demonstrated in acute (n = 2) and chronic (n = 1) bovine model experiments and assessed by improvements in hemodynamics, biocompatibility, flow dynamics, and histopathology. Potential advantages of the MVAD Pump include flow support in the same direction as the native ventricle, elimination of cardiopulmonary bypass, and minimally invasive implantation.
Asunto(s)
Procedimientos Quirúrgicos Cardiovasculares/métodos , Corazón Auxiliar , Hemodinámica , Diseño de Prótesis , Animales , Cadáver , Bovinos , Modelos Animales de Enfermedad , Estudios de Factibilidad , Humanos , Ensayo de Materiales , MiniaturizaciónRESUMEN
OBJECTIVE: The current design trend for left ventricular assist devices (LVADs) is miniaturization, which aims to increase the treatable patient population and enable new treatment indications by reducing surgical trauma and the complications associated with device implantation. The MVAD Pump (HeartWare Inc, Framingham, MA) is a small, axial VAD that uses magnetic and hydrodynamic impeller technology and incorporates wide helical flow channels to minimize shear stress. In this study, we implanted the MVAD Pump in an ovine model to evaluate device hemocomaptiblity, biocompatibility, performance, and safety. METHODS: The MVAD Pump was implanted in an ovine model (n = 9) for 90 days. The pump was implanted through a thoracotomy and secured to the LV apex with a gimbaled sewing ring, which allowed for intraoperative adjustment of the insertion depth and angle of the inflow cannula. Serum analytes and coagulation parameters were analyzed at specific intervals throughout the study period. Pump flow, speed, and power were recorded daily to monitor device performance. Sheep were electively euthanized at 90 days for pathologic and histologic analysis. RESULTS: In this study, results demonstrated the safety, reliability, hemocompatability, and biocompatibility of the MVAD Pump. Nine animals were implanted for 90 ± 5 days. No complications occurred during surgical implantation. Seven of the 9 animals survived until elective sacrifice. Each sheep that survived to the scheduled explant appeared physically normal, with no signs of cardiovascular or other organ compromise. The 2 sheep that were euthanized early showed no evidence of device-related issues. CONCLUSIONS: The MVAD Pump was successfully implanted through a thoracotomy and demonstrated excellent hemodynamic support with no device malfunctions throughout the study period.
Asunto(s)
Corazón Auxiliar , Miniaturización/instrumentación , Diseño de Prótesis , Animales , Remoción de Dispositivos , Hemodinámica/fisiología , Hemoglobinometría , Ensayo de Materiales , Modelos Animales , OvinosRESUMEN
Inadequate research exists regarding testing of a ventricular assist device (VAD) for susceptibility to radiation damage. Specifically, minimal data are available to radiation oncologists prescribing treatment plans for patients with an implanted VAD. As the number of implanted devices increases, patients requiring radiation at tissue sites near or at the device will increase. The purpose of this study is to provide the first analysis of radiation effects of proton beams on VADs. Five left VAD (LVAD) pumps (HeartWare Inc., Miami Lakes, FL) were exposed to proton beam radiation at a calibrated dose rate of 5 Gy/min up to a cumulative dose of 70 Gy. The Heartware LVAD pump recorded parameters including power (W), speed (revolutions/min), and estimated flow (L/min). Analysis of collected data after each irradiation found no deviation in pump parameters from baseline values. The Heartware LVAD pump exhibited no change in device function when directly irradiated by a high energy proton beam. Secondary neutron fluence created in the proton beam during irradiation had no effect on external components including the system controller and batteries powering the Heartware LVAD.
Asunto(s)
Corazón Auxiliar , Terapia de Protones , HumanosRESUMEN
Improved outcomes and quality of life of heart failure patients have been reported with the use of left ventricular assist devices (LVADs). However, little information exists regarding devices in patients undergoing radiation cancer treatment. Two HeartWare Ventricular Assist Device (HVAD) pumps were repeatedly irradiated with high intensity 18 MV x-rays to a dosage range of 64-75 Gy at a rate of 6 Gy/min from a radiation oncology particle accelerator to determine operational stability. Pump parameter data was collected through a data acquisition system. Second, a computerized tomography (CT) scan was taken of the device, and a treatment planning computer estimated characteristics of dose scattering and attenuation. Results were then compared with actual radiation measurements. The devices exhibited no changes in pump operation during the procedure, though the titanium components of the HVAD markedly attenuate the therapy beam. Computer modeling indicated an 11.8% dose change in the absorbed dosage that was distinctly less than the 84% dose change measured with detectors. Simulated and measured scattering processes were negligible. Computer modeling underestimates pretreatment dose to patients when the device is in the field of radiation. Future x-ray radiation dosimetry and treatment planning in HVAD patients should be carefully managed by radiation oncology specialists.
Asunto(s)
Corazón Auxiliar , Neoplasias/radioterapia , Simulación por Computador , Humanos , Aceleradores de Partículas , Dosis de Radiación , Planificación de la Radioterapia Asistida por Computador , Dispersión de Radiación , Rayos XRESUMEN
Implantable left ventricular assist devices provide circulatory support for patients at risk of death from refractory, end-stage heart failure. Rotary blood pumps have been designed for increased reliability and smaller size for use in a broader population of patients than the first-generation pulsatile devices. The design concepts and principle of operation of the HeartWare System are discussed. The HeartWare Ventricular Assist System (HVAD) is a small centrifugal flow pump with a displacement volume of 50 ml and an output capacity of 10 L/min. A unique wide-blade impeller is suspended by hybrid passive magnets and hydrodynamic forces. An integrated inflow cannula is inserted into the left ventricle and is held in position by an adjustable sewing ring; the pump is positioned in the pericardial space. The 10-mm outflow graft is anastomosed to the ascending aorta. External system components include the microprocessor-based controller, a monitor, lithium-ion battery packs, alternating current and direct current power adapters, and a battery charger. Physiologic control algorithms are incorporated for safe operation. Preclinical life cycle tests have shown the HVAD to be highly reliable. This system design offers reliability, portability, and ease of use for ambulatory patients.
Asunto(s)
Corazón Auxiliar , Diseño de PrótesisRESUMEN
Pulsatile ventricular assist devices have successfully provided circulatory support for many patients throughout the past quarter century; however, persistent complications have hindered expanded clinical application of this technology. Although the use of smaller, continuous-flow ventricular assist device pumps has reduced the frequency and severity of some adverse events, design enhancement may further improve outcomes for patients who require long-term left ventricular support. One new product, the HeartWare, Inc., miniature ventricular assist device, features a wide-bladed rotor design in an axial-flow pump with a strong, passively suspended magnetic rotor. The operating range of 16,000 to 28,000 rpm can provide up to 10 L/min of flow. The wide blades portend minimal cellular trauma.This new device has not yet been approved for use in human beings. As a test, we implanted it in a calf, and we continuously monitored the device's performance and the hemodynamic results over 30 days. No mechanical failure occurred, and no thrombi were noted upon explantation of the device. The animal's circulation was stable during the test period, and no end-organ abnormalities were found upon autopsy. The potential benefits of this miniature ventricular assist device are its increased availability to a broader patient population, a lower risk of infection, simplified implantation procedures, and improved durability. Further in vivo testing is planned. Herein, we discuss the unique design of the HeartWare miniature ventricular assist device, our feasibility study of its performance, and the possibilities for its use in human beings.